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SUMMARY 
In a single-blind, randomised, parallel-group study comparing the efficacy and tolerability of dothic-
pin (50-150 mg per day) and imipraniine (50-150 mg per day) for6weeks, involving 60 adult patientswith 
depression, it was observed that dothiepin was comparable to imipramine in terms of efficacy as assessed by 
Hamilton Rating Scale for depress ion, global scale for severty of illness and clinifian's overall assessment of 
efficacy. Dothiepin was found to have a significantly earlier onset of anxiolytic action compared to imipra-
mine. Dothiepin was well tolerated. 
Dothiepin (Prothiadenn) is a tri-
cyclic antidepressant which was first 
synthesized by Rajsner and protiva in 
1962. It is a thio analogue of anv'trip-
tyline. Early clinical work on dothiepin 
suggested that the drug has both anti-
depressant and anxiolytic properties 
(Rydzynski, 1966). In subsequent clinical 
studies, the drug has been shown to be 
an effective antidepressant with associated 
anx'olytic action in depression fLipsedge 
et al., 1971; Johnson et al., 1973 and 
Sharma, 1981). Dothiepin has been 
shown to be well tolerated in clinical 
studies (Goldstein and Claghorn, 1980). 
The present study was planned 
to evaluate the efficacy ard 
safety of dothiepin in comparison to 
imipramine, a commonly used tricyclic 
antidepressant, in patients suffering from 
depression. 
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Material and Methods 
The study was conducted at the 
Department of Psychiatry, S.M.S. Medi-
cal College, Jaipur. In this single-blind 
parallel group study, 60 patients suffering 
from depression as a primary illness and 
not as a secondary manifestation of any 
other psychiatric illness, and in whom 
treatment with antidepressants was deemed 
necessary, were included, after obtaining 
their informed corser t. The duration of 
the trial was six weeks. 
Selection of the patients in the study 
was as per the criteria of Feighner et al. 
(1972). The exclusion criteria were 
pregnancy, lactation, prostatic hypertro-
phy, glaucoma, renal, hepatic or cardio-
vascular disorders, history of epilepsy, 
history of allergy to trial drugs, receipt of 
antidepressant medication during the 
preceding 14 days of commencing the 
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trial, an immediate danger of Suicide and 
need for electroconvulsive therapy for the 
present episode. 
The patients admitted into the trial 
were randomly allocated to receive either 
im'pratnine or dothiepin- The following 
was the dosage adm'nistration of trial 
therapy : Day 1 to Day 3 : 50 mg as a 
single dose at night; Day 4 to Day 14 : 
75 mg as a single dose at night; Day 15 
(week 3) to Day 42 (week 6) : If response 
was considered inadequate to single dose 
of 75 mg daily, the dose of the drug was 
increased gradually, as per the clinician's 
judgement, upto 150 mg per day. The 
dose in excess of 75 mg was given in divi-
ded doses. 
Clinical assessment of drug efficacy 
was based or the following parameters; 
these being carried out by an independent 
psychiatrist who was not aware of the 
drug received by the patient : 
(1) Severity of depressive illness using 
Hamilton Rating Scale for depre-
ssion (Hamilton, 1960) prior to and 
at weekly intervals after commen-
cing drug therapy. 
(2) Global scale for severity of illness— 
using the snb
:ective judgement of the 
clinician as 0—not ill, 1—mild, 
2—moderate, 3—severe and 4— 
very severe. This was recorded 
prior to initiation of drug therapy 
and thereafter at weekly intervals. 
(3) Clinician's overall assessment of 
effiicacy—recorded at the end of 6 
weeks of drug therapy on a 0-6 scale 
as 0—symptoms cleared, 1—marked 
improvement, 2—moderate improve-
ment, 3—slight improvement, 4— 
no change, 5—worse and 6—with-
drawn. 
Assessment of tolsrab'lity and safety 
was carried out u
;ing the following para-
meters : 
(I) Side-efFects —those observed bv the 
physician or volunteered by the pa-
tient were recorded and the severity 
graded as 1—mild, 2—moderate, 
or 3—severe. A checklist of symp-
toms was completed prior to initia-
tion of drug therapy so as to rule 
ovt disease-related symptoms being 
reported as 'drug' side-effects. 
(2) Cardiovascular cxam'nat^—this 
included recording the supine and 
erect blood pressure and pulse rate 
prior to and at weekly iitervals 
during therapv. A 12-lead electro-
cardiogram was recorded before 
commencing drug therapy and 
after 3 and P weeks of therapy. 
(3) Laboratory investigations—routine 
friematological and biochemical 
investigations and Urnalysis were 
carried out before and after drug 
therapy. 
Results 
Sixty patients were enrolled in the 
study of whom 32 patients were random-
ised to receive dothiepin and 28 to receive 
iroipramine. Five patients in each group 
did not fullfill the protocol requirements 
and were excluded from the analysis. 
Five patients receiving dothiepin and 4 
receiving imipraminc failed to attend the 
clinic regula
rly and therefore, their data 
were excluded for analysis of efficacy. 
Three patients receiving dothiepin and 
one receiving imipramire developed hypo-
manic/manic features such as elated mood, 
increased psychomotor activity, grand
:ose 
delusio/i, distractab
:lity and flight of 
ideas and hence could not continue their 
med'eation. It is know.a that tricyclic 
antidepressants nvay unmask mania in 
bipolar disorder (American Medical 
Association, 1986)- The data of these 
patients have not been included for effi-
cacy assessments but have been included 
in safety evaluation. Thus the data for 
19 patients in the dothiepin group and 
18 in the imiprarnine group were analy-DOTMIEPIN AND IMIPRAMiNE IN DEPRESSION 
Table 1. Demographic details of patienls receiving dothiepin and imipramine 
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Parameter  Dothiepin (n=19) Imipramine (n=»18) 
Age (years) Mean+S.E.M. 
Sex (Male : Female) 
Body weight (kg) Mean+S.E.M. 
Duration of disease (months ) Mean+S.E.M. 
No. of previous episodes Mean+S.E.M. 
No. of patients with suicidal attempts 
Employment status-No. of patients working: those not working 
37.0*±2.40 
10:9 
55.2±2.24 
7.4+2.61 
1.2±0.38 
3 
working t»;13 
45.8*±2.56 
10:8 
49.5+2.03 
4.1 + 1.34 
1.0+0.32 
2 
4:14 
*p<0.05 (t test) 
sed for efficacy ar.d 27 in the dothiepin 
and 23 in the imipramine groups for 
tolerability. 
The demographic details of the two 
treatment groups are presented in Table 
1. The groups were comparable except 
that patients in the imipramine group 
(mean age 45.8 years) were older com-
pared to those in the dothiepin group 
(mean age 37.0 years'!. The dosage of 
the two drugs used in the study ranged 
from 50-150mg per day. 
CLINICAL EFFICACY 
Hamilton Rating Scale : The mean 
total Hamilton scores for dothiepin 
and imipranvn^ treated groups of patients 
before and during 6 weeks of drug the-
rapy are depicted in Figure 1. Both the 
drugs produced significant reduction in 
the mean total Hamilton scores at each 
assessment period during therapy (weeks 
1-6) compared to the baseline scores 
(p<0.01, Wdcoxon matched-pairs, sigied-
ranks test). There was no significant 
difference between the two groups in 
terms of reduction in total Hamilton 
scores (p>0.05, Mann-Whitney test). 
Figure 1 MMn ToUl HwnMon Scon<« SEMI 
The anxiety scores were analysed 
separately and are graphically presented 
in Figure 2. It was observed that do-
thiepin resulted in significant reduction 
in anxiety scores from week 1 to week 6 
of therapy; with imipramine, a signifi-
cant reduction was observed only from 
week 3 of therapy (p<0.05, Wilcoxon 
matched-pairs, signed-rank test). The 
difference between the two drugs was 
-ignificant in favour of dothiepin at week 154  J. N. WAS it d. 
1 of therapy suggesting an earlier onset 
of anxiolytic effect (p<0.05, Mann-
Whitncy test). 
FfMl AlUM* SCWM (MM* . SEM) 
Olobal Scale for Severity of Ill-
ness : Both dothiepin and imipramine 
produced significant reduction in severity 
of illness from week ] of therapy (Table 
2). The patients in the dothiepin group 
had a significantly greater severity score 
prior to comtnencirg drug therapy than 
those in the imipramine group (p<0.05, 
Mann-Whitney test). Therefore, the per-
centage from pre-therapy was calculated 
and used for comparison between the two 
groups. The difference between the two 
drugs did not reach a level of statistical 
significance in this regard (p>0.05, 
Mann-Whitney test). 
Clinician's Overall Assessment of 
Efficacy : All 19 patients (100%) in 
the dothiepin group and 16 patients (88.9 
%) in the imipramine group had impro-
ved at the sixth week of assessment, as 
rated by the clinician (Table 3). The 
difference between the two groups was 
not statistically significant (p>0.05, 
Mann-Whitney test). 
TOLERABILITY 
Side-tfftcts : Oulf of 27 evalua-
ble patients receiving dothiepin, J4 repor-
ted side-effects, while 12 of the 23 evalu-
able patients receiving imipramine repor-
ted side-effects (p>0.05, X
2 test). With 
dothiepin, 14 patients complained of a 
total of 21 side-effects and with imipra-
mine, 12 patients complained of a total of 
25 side-effects. The side-effects reported 
were typical of those reported with tricy-
clic antidepressants (Table 4). The mean 
composite severity score (-[-S.E.M.) was 
0.93±0.2 for dothiepin and 1.34±0.39 
for imipramine. Total number of side-
effects and severity of side-effects was 
higher with imipramine than with do-
thiepin; however, the difference between 
the two drugs did not reach a level of 
statistical significance (p<0.05, Mann-
Whitney test). 
Cardiovascular Examination : The 
drugs under study did not affect the 
pulse rate, supine and erect blood pres-
sure to a clinically significant level, except 
for one patient receiving imipramine who 
experienced postural hypotension and 
sudden fall during end of week 1 of the-
rapy. Imipramine therapy was conti-
nued in this patient for six weeks. No 
EGG changes were observed in either 
the dothiepin or imipramine groups. 
Laboratory Inoetigations i Haemato-
logical and biochemical investigations 
and urinalysis showed no clinically signi-
ficant changes. 
Discussion 
The results of the study corroborated 
the findings of Simetal. (1975) and Eilen-
berg (1980) who have also observed that 
dothiepin is comparable in efficacy to 
imipramine. In this study, dothiepin was 
found to have an earlier onset of anxio-
lytic action compared to imipramine. The 
earlier onset of anxiolytic action of do-
thiepin has also been reported by Sharma 
(1981) and Vencovsky et al. (1964). This 
feature of dothiepin will be of benefici-DOTHIEPIN AND IMIPRAMINE IN DEPRESSION 
Table 2. Global scale for seierity of illness 
Drug 
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Severity score Mean±S.E.M. 
Treatment week 
Pre-therapy 
1. 
Dothiepin 2.1 1.-40 0.9 0.5 0.4 0.5 0.3 
(n=19) . ±0.05* ±0.14** ±0.13** ±0.12** ±0.14** ±0.14** ±0.13** 
Imipramine 1.7 1.1 0.9 0.8 0.4 0.4 0.5 
(n = 18) ±0.16* ±0.14** ±0.14** ±0.20** ±0.14** ±0.17** ±0.17** 
*p<0.05, (Mann-Whitney test) 
**p<0.05 (Wilcoxon matched-pairs, signed-rank test). 
Table 3. Clinicians overall assessment of 
efficacy 
Table 4. Mature of side-effects with dothiepin 
and imipramine 
Clinician's Assessment 
No. (%) 6F patients 
Dothiepin Imipramine 
(n=-19) (n=18) 
Symptoms cleared 
Marked improvement 
No change 
12(63.2) 10(55.6) 
7(36.8) 6(33.3) 
2(11.1) 
p<0.05, (Mann-Whitney test) 
al value since anxiety is frequently asso-
ciated with depression and early relief 
of anxiety is likely to aid patient compli-
ance. 
Dothiepin has been reported to have 
lower incidence of side-effects (Sim et al., 
1975 and Eilenberg, 1980) and lesser 
severity of side-effects compared to imi-
pramine (Sim et al., 1975). In this study 
the frequency and severity of side-effects 
were less with dothiepin compared to 
im'pramine but this difference did not 
reach a level of statistical significance. 
In conclusion, dothiepin was com-
parable to imipramine in terms of efficacy 
with an earlier onset of anxiolytic action 
and it was well tolerated. 
Nature of side effect Dothiepin Imipramine 
(n=27) (na*23) 
Dryness of mouth 
Constipation 
Urinary difficulty 
Nausea 
Vomiting 
Anorexia 
Indigestion 
Drowsiness 
Restlessness 
Tremors 
Mania 
Giddiness 
Sweating 
Sudden fall 
6 
3 
1 
1 
1 
1 
1 
1 
1 
3 
1 
3 
1 
1 
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